API Bulk Drug (Medium Scale) Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Api bulk drug (medium scale) sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹14.7 crore - ₹219 crore CapEx this DPR captures:

• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The API bulk drug medium-scale sector in India is characterized by a segmented operational structure that blends captive production with merchant supply. Captive production, where pharmaceutical companies manufacture APIs for their own formulations, represents 61.55% of the market share, reflecting the deep vertical integration practiced by large Indian pharma houses. The low and medium potency molecule segment dominates the market, accounting for approximately 85.90% of market volume and size, while high-potency APIs (HPAPIs) and complex molecules such as peptides including Semaglutide, Tirzepatide, and Liraglutide, as well as oligonucleotides, are emerging as high-value growth sub-segments.

The sector also encompasses the Contract Development and Manufacturing Organization (CDMO) space, which is gaining prominence as global innovators seek reliable outsourcing partners for custom synthesis and advanced intermediate manufacturing.</p><p>Regionally, West India holds the leading market share at 40.5%, driven by the high concentration of manufacturing facilities in Maharashtra and Gujarat. The broader India API market is estimated at approximately USD 13.5 billion to USD 14.18 billion, representing the domestic production landscape. India's pharmaceutical sector overall was valued at USD 68.38 billion in 2025, and the country exported drugs and pharmaceuticals worth USD 30.47 billion in FY 2024-2025, recording a 9.4% year-over-year increase.

On the global stage, India accounts for 44% of all API manufacturers worldwide, compared to 22% for China and only 9% for domestic US manufacturing, highlighting India's outsized role in global API supply. Indian facilities also account for 57% of all WHO-prequalified API manufacturing sites globally, reinforcing the sector's compliance credentials. In terms of profitability, gross profit margins for medium-scale API manufacturers range from 10% to 15%, while net profit margins stand at 5% to 10%.

Raw material costs constitute 55% to 65% of total operating expenses, utility costs account for 10% to 15%, and other operating costs make up 20% to 35%.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth

<p>Medium-scale API bulk drug manufacturing in India employs a technology spectrum that spans conventional chemical synthesis to advanced biocatalytic and continuous flow processes. Setting up a mid-scale advanced API manufacturing facility requires a total capital expenditure in the range of INR 50 crores to INR 200+ crores (USD 5 million to USD 50 million), depending on molecular complexity, degree of automation, and the level of WHO-GMP and international regulatory compliance achieved. The capital cost structure for a mid-scale facility in the INR 50-80 crore range typically allocates substantial portions to reactor systems, purification infrastructure, quality control laboratories, and effluent treatment plants that meet MoEF&CC standards.</p><p>The manufacturing process involves multi-step synthesis beginning with Key Starting Materials (KSMs), progressing through intermediate stages, and culminating in the final API, followed by purification, crystallization, drying, and stringent quality testing.

Technology adoption trends in the sector include the strategic pivot toward complex generics, peptides such as Semaglutide, Tirzepatide, and Liraglutide, oligonucleotides, and High-Potency APIs (HPAPIs) as high-value alternatives to traditional small-molecule APIs. Skilled technical and operational personnel comprise approximately 60% to 70% of the total plant workforce, with the remaining 30% to 40% comprising general or semi-skilled labor, reflecting the skilled labor intensity of modern API manufacturing. The sector is also seeing increased adoption of continuous manufacturing technologies and process intensification strategies to improve yields, reduce waste, and enhance cost competitiveness against global peers.</p>

The project CapEx band of ₹14.7 crore to ₹219 crore encompasses facility scales from 5 MT/month single-product API to 200 MT/month multi-product CDMO operations. KAMRIT recommends a phased CapEx deployment starting at ₹35-50 crore for a 30-50 MT/month multiproduct API facility targeting domestic formulation customers and UN agency procurement, transitioning to ₹80-120 crore expansion for regulated market (USFDA/EU) capability. Means of Finance: Debt-to-Equity ratio of 3:1 is achievable for projects with long-term supply agreements with rated pharmaceutical companies, reducing to 2:1 for greenfield facilities without revenue track record. SIDBI provides dedicated pharma MSME financing at MCLR+50-100 bps through its Pharma Tech Fund, complementable with state-level schemes including Telangana's Ts-iPASS incentives (15% capital subsidy on CapEx up to ₹20 crore) and Gujarat's CMGI scheme (25% subsidy on pollution control equipment). Working capital requirement for API manufacturing: 90-120 day raw material inventory cycle for imported starting materials (China-sourced KSMs), 45-60 day finished goods cycle for quality release quarantine, and 60-90 day receivable cycle from domestic formulation customers versus 30-45 days for export customers. ICICI Bank and Axis Bank have established dedicated pharma sector desks offering LC facilities for KSM imports and buyer-supplier financing structures with top-20 pharmaceutical formulators. NABARD refinancing for eligible MSME API units provides 2-3% interest subvention on term loans. Break-even analysis for the ₹50 crore facility scenario: 62% capacity utilization required at 28% EBITDA margin.

<p>Despite the compelling opportunity landscape, medium-scale API bulk drug manufacturers in India face a spectrum of risks that require careful mitigation. Raw material cost volatility represents the most immediate operational risk, as raw materials constitute 55% to 65% of total operating expenses, and India's heavy dependence on Chinese imports for KSMs and intermediates (73.71% share, worth USD 3.20 billion in FY 2024-25) exposes manufacturers to supply disruptions, price fluctuations, and geopolitical tensions. Fluctuating international demand-supply trends, lower utility costs, and borrowing costs also influence API price variations, creating revenue unpredictability for medium-scale operators with thinner balance sheets compared to larger peers.</p><p>Regulatory compliance costs are substantial and escalating.

Mandatory adherence to CDSCO, WHO-GMP, US FDA, and other international regulatory standards requires continuous investment in quality infrastructure, documentation systems, and skilled personnel. The 2020 MoEF&CC draft notifications regulating effluent limits for bulk drug manufacturers impose additional environmental compliance costs, while SEBI's 2023 BRSR guidelines mandate sustainability reporting, adding disclosure and operational overhead. The 18% GST rate on APIs and bulk drugs, effective from September 22, 2025, compresses margins in a sector where net profit margins already range narrowly from 5% to 10%.

Capital intensity remains a barrier, as setting up a compliant mid-scale facility requires INR 50 crores to INR 200+ crores, and the sector's gross profit margins of 10% to 15% limit the speed of capital recovery. Competition from the unorganized segment, which undercuts prices due to lower compliance costs, poses an ongoing threat to organized medium-scale manufacturers. Additionally, the broader global API market is subject to pricing pressures from Chinese manufacturers who benefit from economies of scale and subsidized inputs, making it challenging for Indian medium-scale players to compete solely on cost.

Currency fluctuations, particularly INR-USD volatility, further impact export competitiveness for a sector that derives significant revenue from overseas markets.</p>